{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17044", "batch_size": 200, "batch_pos": 15, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment describes details of a deal.", "method": "llm_batch", "batch_id": "batch_2_20512", "batch_size": 200, "batch_pos": 200, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "No moderate verb paired with explicit scale/impact.", "method": "llm_batch", "batch_id": "batch_3_4816", "batch_size": 200, "batch_pos": 141, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_17564", "batch_size": 200, "batch_pos": 138, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "The segment reports details of vaccine deal but contains no explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_20544", "batch_size": 200, "batch_pos": 135, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_2220", "batch_size": 200, "batch_pos": 110, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation about risk or impact.", "method": "llm_batch", "batch_id": "batch_7_20812", "batch_size": 200, "batch_pos": 97, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes securing vaccine doses (preparedness/stockpiling) ('deal secures up to 665,000 doses... includes an option for a further 40 million vaccines') without explicit calming keywords.", "method": "llm_batch", "batch_id": "batch_8_17904", "batch_size": 200, "batch_pos": 158, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
